Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
Postoperative circulating tumor DNA (ctDNA) positivity strongly predicts worse survival in stage III colon cancer, with ctDNA-positive patients showing sixfold higher recurrence risk. Among ...
Pharmaceutical Technology on MSN
Innovent receives NMPA approval for Tabosun colon cancer treatment
Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...
This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback